Cowen reiterated their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note published on Wednesday. Cowen currently has a $165.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Alexion Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, March 7th. Guggenheim began coverage on shares of Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a neutral rating and a $135.00 price target on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 12th. Morgan Stanley lifted their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an overweight rating in a report on Tuesday, February 12th. Finally, Credit Suisse Group reaffirmed a buy rating and issued a $156.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, January 22nd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $160.73.

Shares of ALXN stock opened at $136.09 on Wednesday. The company has a market cap of $30.41 billion, a P/E ratio of 19.19, a price-to-earnings-growth ratio of 1.00 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.48 and a current ratio of 2.88. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.60 by $0.54. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. Alexion Pharmaceuticals’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the company posted $1.48 earnings per share. Sell-side analysts anticipate that Alexion Pharmaceuticals will post 8.51 earnings per share for the current fiscal year.

In other news, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $126.00, for a total transaction of $252,000.00. Following the completion of the sale, the chief accounting officer now directly owns 5,020 shares in the company, valued at $632,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ludwig Hantson sold 3,244 shares of Alexion Pharmaceuticals stock in a transaction on Monday, December 31st. The stock was sold at an average price of $95.85, for a total transaction of $310,937.40. Following the sale, the chief executive officer now owns 150,696 shares of the company’s stock, valued at $14,444,211.60. The disclosure for this sale can be found here. Insiders sold 8,488 shares of company stock worth $873,875 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Several large investors have recently bought and sold shares of ALXN. Captrust Financial Advisors acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $31,000. NuWave Investment Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 851.9% during the fourth quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 460 shares during the period. Kaizen Advisory LLC lifted its stake in shares of Alexion Pharmaceuticals by 22.2% during the fourth quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 111 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $68,000. Finally, We Are One Seven LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $79,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: No Load Funds

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.